Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron Pharmaceuticals

Billions in Buybacks: 4 Stocks Rewarding Shareholders Now

These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap.

MarketBeat

What to Expect From Regeneron Pharmaceuticals's Q4 2024 Earnings Report

Regeneron Pharmaceuticals is slated to release its fourth-quarter results next month, and analysts forecast a single-digit dip in its bottom-line figure.

Barchart

What to Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings Report

Regeneron Pharmaceuticals is slated to release its fourth-quarter results next month, and analysts forecast a single-digit dip in its bottom-line figure.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Regeneron Culls Losses After High-Dose Eylea Sales Disappoint

Regeneron stock recovered Monday after the drugmaker preannounced light sales of a high-dose version of eye drug Eylea.

Investors Business Daily

3 S&P 500 Stocks to Buy in 2025 With Big Rebound Potential

As markets rise, a handful of resilient stocks that were bruised could rebound over 30%, powered by strong fundamentals and bullish prospects.

Barchart

3 Nasdaq-100 Stocks With 25% to 53% Upside Potential

These three Nasdaq-100 Stocks shine as prime opportunities as analysts forecast 25% to 53% upside potential.

Barchart

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Despite Regeneron Pharmaceuticals’ significant underperformance relative to Nasdaq recently, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

Benzinga

3 Biotech Stocks Set to Revolutionize Medicine

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

StockNews.com

3 Biotech Stocks That Could Deliver Big Gains

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of new therapeutics, and increased R&D spending on treatments for new and rare diseases. Hence, investors should consider strong biotech stocks such as Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which could deliver big…

StockNews.com

Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling

Tesla led the S&P 500 index on Monday, moving toward a buy point. Regeneron Pharmaceuticals tumbled on a surprise court ruling.

Investors Business Daily

How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

Barchart

Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms

Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.

Investors Business Daily

Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised

The Dow fell after initially rising on the PPI inflation report on the stock market today. Analysts hiked Microsoft and Nvidia price targets.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Plunge into Profits With These 3 Biotech Stocks

The biotech industry's robust growth potential is driven by substantial pharma research and development, swift technological advancements, and lucrative government support. Given this backdrop, quality biotech stocks ProQR Therapeutics N.V. (PRQR), Regeneron Pharmaceuticals (REGN), and Corcept Therapeutics (CORT) could be solid buys now. Read on….

Investors Business Daily

The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High

Regeneron Pharmaceuticals put up a commanding fourth-quarter beat on Friday, helped by Praluent. REGN stock is trading at an all-time high.

Top News

Eylea Sales Soar, Regeneron Breaks Records with Eylea Sales Soar, Regeneron Breaks Records with Top News.34 Billion!.34 Billion!

Regeneron's Q4 sales of Eylea skyrocketed to a staggering Eylea Sales Soar, Regeneron Breaks Records with Top News.34 Billion!.34 billion in the U.S., sending shockwaves through the pharmaceutical industry. Incredible suc...

Investors Business Daily

Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers

Regeneron Pharmaceuticals topped third-quarter forecasts on Thursday, helped by a strong launch from its high dose of Eylea. REGN stock rose.

StockNews.com

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on.

Investors Business Daily

Regeneron Bulls, Bears Clash: Will Biotech Get Eylea Mojo Back?

With Regeneron earnings due Nov. 2, the big debate is whether the company will get its mojo back in its core eye disease treatment business?

Investors Business Daily

Regeneron Pharmaceuticals Stock Earns 85 RS Rating

A Relative Strength Rating upgrade for Regeneron Pharmaceuticals shows improving technical performance.

Investors Business Daily

Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough'

Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.